Marco daCosta DiBonaventura (Marco DiBonaventura, M DiBonaventura)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Multiple Myeloma

Clinical Practice

Clinical Decision Support

Atopic Dermatitis

Top Venues

Future oncology (London, England)

British journal of haematology

American journal of clinical dermatology

Dermatology and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology 204 (5) (2024)
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology 204 (5) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Luciano José Megale Costa, Thomas William LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan P Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco daCosta DiBonaventura
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma. Future oncology (London, England) 20 (17) (2024)
Gil Yosipovitch, Melinda J Gooderham, Pamela Guglielmini, Luz Fonacier, Jacek Cezary Szepietowski, Mette Deleuran, Giampiero Girolomoni, John C Su, Andrew G Bushmakin, Joseph Christopher Cappelleri, Claire Feeney, Gary Chan, Andrew J Thorpe, Hernan Valdez, Pinaki Biswas, Ricardo Rojo, Marco daCosta DiBonaventura, Daniela E Myers
Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2. American journal of clinical dermatology (2023)
Jashin J Wu, Marie-Hélène Lafeuille, Bruno Emond, Iman Fakih, Mei Sheng Duh, Joseph Christopher Cappelleri, Natalie Yin, Claire Feeney, Daniela E Myers, Marco daCosta DiBonaventura
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis. Advances in therapy 39 (9) (2022)
Shawn G Kwatra, David Gruben, Selwyn Fung, Marco daCosta DiBonaventura
Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis. Advances in therapy 38 (3) (2021)
Jonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, Gil Yosipovitch, Sonja Ständer, Hernan Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E Myers, Claire Feeney, Marco daCosta DiBonaventura
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes. American journal of clinical dermatology 22 (4) (2021)
Jonathan Ian Silverberg, Jacob Pontoppidan Thyssen, K Fahrbach, K Mickle, J C Cappelleri, W Romero, M C Cameron, D E Myers, C Clibborn, Marco daCosta DiBonaventura
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (9) (2021)
Alessandro Armuzzi, Miriam Tarallo, James Lucas, Daniel Bluff, Benjamin Hoskin, Danielle Bargo, Joseph C Cappelleri, Leonardo Salese, Marco daCosta DiBonaventura
The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe. BMC gastroenterology 20 (1) (2020)
Giampiero Girolomoni, Thomas Luger, Audrey Nosbaum, David Gruben, William Romero, Lyndon John Llamado, Marco daCosta DiBonaventura
The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey. Dermatology and therapy 11 (1) (2020)
Lawrence F Eichenfield, Marco daCosta DiBonaventura, Jason Xenakis, Marie-Helene Lafeuille, Mei Sheng Duh, Iman Fakih, Mark Levenberg, Joseph C Cappelleri, Vanja Sikirica
Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. Dermatology and therapy 10 (4) (2020)